摘要
To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer patients.Recent data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.
